Pardes Biosciences Reports First Quarter 2023 Financial Results
- Pardes Biosciences reported a decrease in net loss for Q1 2023 compared to the previous year. Research and development expenses decreased by $0.2 million and general and administrative expenses decreased by $1.4 million. The company's cash and cash equivalents as of March 31, 2023, were $172.2 million.
- None.
CARLSBAD, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS) today reported financial results for the first quarter ended March 31, 2023.
“As previously announced this year, Pardes Biosciences has initiated a process to evaluate strategic alternatives to maximize shareholder value that may potentially result in changes to our business strategy,” said Thomas G. Wiggans, Chief Executive Officer and Chair of Pardes Biosciences.
First Quarter 2023 Financial Results
Pardes reported a net loss of
Research and development expenses were
General and administrative expenses were
Pardes’ cash, cash equivalents and short-term investments as of March 31, 2023, were
As of April 30, 2023, Pardes' preliminary cash, cash equivalents and short-term investments totaled approximately
About Pardes Biosciences, Inc.
Pardes Biosciences is a biopharmaceutical company that has been focused on discovering, developing and commercializing novel oral anti-viral therapeutics to improve the lives of patients suffering from life-threatening disease, starting with COVID-19. For more information, please visit www.pardesbio.com.
Availability of Other Information about Pardes Biosciences
Pardes Biosciences intends to use the Investors page of its website (https://ir.pardesbio.com) as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Pardes Biosciences’ Investors website, in addition to following Pardes Biosciences’ press releases, Securities and Exchange Commission (SEC) filings, public conference calls, presentations and webcasts.
Forward Looking Statement
This press release contains statements that relate to future events and expectations and, as such, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this press release, the words “believe,” “intend,” “may,” “plan,” “possible,” “predict,” “should,” “will,” and similar expressions and their variants, as they relate to the Company, may identify forward-looking statements. All statements that reflect Pardes Biosciences’ (Pardes) expectations, assumptions or projections about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding the Company’s preliminary cash, cash equivalents and short-term investments as of April 30, 2023, statements regarding Pardes' intent to review strategic alternatives and Pardes' expectation that general and administrative expenses will decrease. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the completion of the quarterly review of the Company’s financial statements for the quarter ended June 30, 2023; volatility and uncertainty in the capital markets for biopharmaceutical companies; Pardes' ability to execute its planned exploration and evaluation of strategic alternatives; availability of suitable third parties with which to conduct contemplated strategic transactions; whether the Company will be able to pursue a strategic transaction, or whether any transaction, if pursued, will be completed on attractive terms or at all; whether Pardes' plans will provide the intended benefits and cost savings; and other risks and uncertainties described under the heading “Risk Factors” in Pardes’ Annual Report on Form 10-K for the year ended December 31, 2022, Quarterly Report on Form 10-Q to be filed for the quarter ended March 31, 2023, and other filings subsequently filed with the U.S. Securities and Exchange Commission. The statements in this press release speak only as of the date of this press release, even if subsequently made available by Pardes on its website or otherwise. Pardes disclaims any intention or obligation to update publicly any forward-looking statements, whether in response to new information, future events, or otherwise, except as required by applicable law. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements.
Investor Contact:
ir@pardesbio.com
Select Financial Information:
Pardes Biosciences, Inc.
Condensed Statements of Operations
(Unaudited)
(in thousands, except share and per share amounts)
Three Months Ended March 31, | ||||||||
2023 | 2022 | |||||||
Operating expenses: | ||||||||
Research and development | $ | 12,980 | $ | 13,199 | ||||
General and administrative | 6,829 | 8,226 | ||||||
Total operating expenses | 19,809 | 21,425 | ||||||
Other income: | ||||||||
Interest and other income, net | 2,004 | (15 | ) | |||||
Net loss | $ | (17,805 | ) | $ | (21,440 | ) | ||
Net loss per share, basic and diluted | $ | (0.30 | ) | $ | (0.38 | ) | ||
Weighted-average number of common shares - basic and diluted | 59,766,037 | 57,039,069 | ||||||
Pardes Biosciences, Inc.
Condensed Balance Sheets
(Unaudited)
(in thousands)
March 31, | December 31, | |||||||
2023 | 2022 | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 47,164 | $ | 59,284 | ||||
Short-term investments | 125,067 | 138,056 | ||||||
Prepaid expenses and other current assets | 3,914 | 3,062 | ||||||
Total current assets | 176,145 | 200,402 | ||||||
Other assets | — | 219 | ||||||
Total assets | $ | 176,145 | $ | 200,621 | ||||
Liabilities and stockholders' equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 3,715 | $ | 4,929 | ||||
Accrued expenses | 7,700 | 15,496 | ||||||
Total current liabilities | 11,415 | 20,425 | ||||||
Total liabilities | 11,415 | 20,425 | ||||||
Stockholders' equity: | ||||||||
Preferred stock | — | — | ||||||
Common stock | 6 | 6 | ||||||
Additional paid-in capital | 330,710 | 328,372 | ||||||
Accumulated other comprehensive loss | (23 | ) | (24 | ) | ||||
Accumulated deficit | (165,963 | ) | (148,158 | ) | ||||
Total stockholders' equity | 164,730 | 180,196 | ||||||
Total liabilities and stockholders' equity | $ | 176,145 | $ | 200,621 |
FAQ
What were Pardes Biosciences' Q1 2023 financial results?
What caused the decrease in net loss for Pardes Biosciences?
What are Pardes Biosciences' cash and cash equivalents as of March 31, 2023?
Will Pardes Biosciences' general and administrative expenses decrease in the near term?